GlassScriptPhysician profile
Donna S Shields
NPI 1396718987
$4,229.67
in general payments reported to CMS, 2019-2025
20 companies · $1,311 in 2025
The $1,311 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $90.53 · 2022: $888 · 2023: $810 · 2024: $1,130 · 2025: $1,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,177 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,176.50 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,678.48 | 2021-2025 | |
| Janssen Biotech, INC. | $578.56 | 2023-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $571.70 | 2021-2025 | Entyvio, Gattex |
| Phathom Pharmaceuticals, INC. | $269.42 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $267.47 | 2021-2025 | Livdelzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $239.75 | 2021-2024 | Trulance |
| Boston Scientific Corporation | $105.52 | 2022 | |
| Novo Nordisk INC | $102.19 | 2022 | |
| Ardelyx, INC. | $90.08 | 2024-2025 | Ibsrela |
| Qol Medical, LLC | $86.60 | 2022-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $36.06 | 2025 | |
| Intercept Pharmaceuticals, INC. | $31.42 | 2021-2023 | Ocaliva |
| Ferring Pharmaceuticals INC. | $30.67 | 2022-2023 | Rebyota |
| Daiichi Sankyo INC. | $27.84 | 2022 | |
| Celgene Corporation | $22.74 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $20.97 | 2025 | Suflave |
| Fresenius Kabi USA, LLC | $19.15 | 2023 | Idacio |
| Lilly USA, LLC | $18.05 | 2024 | Omvoh |
| Merck Sharp & Dohme LLC | $16.56 | 2023 | Dificid |
| Amgen INC. | $16.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Shields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.